Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301783 | 0.93 | P2RX4 (0.79) | P2RX4 | |
| SCHEMBL18301851 | 0.93 | P2RX4 (1.00) | P2RX4 | |
| SCHEMBL31290093 | 0.93 | P2RX4 (1.00) | P2RX4 | |
| SCHEMBL30591486 | 0.91 | P2RX4 (0.82) | P2RX4 | |
| SCHEMBL18301621 | 0.91 | P2RX4 (0.82) | P2RX4 | |
| SCHEMBL18301808 | 0.90 | P2RX4 (0.75) | P2RX4 | |
| SCHEMBL18301886 | 0.89 | P2RX4 (1.00) | P2RX4 | |
| SCHEMBL18301698 | 0.89 | P2RX4 (0.85) | P2RX4 | |
| SCHEMBL18301928 | 0.89 | P2RX4 (0.85) | P2RX4 | |
| SCHEMBL18301695 | 0.89 | P2RX4 (0.85) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | claimed |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-29 | — | — | US | claimed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3307715-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198374-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | P2RX4 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.